United States - English - NLM (National Library of Medicine)

allure labs, inc - zinc oxide (unii: soi2loh54z) (zinc cation - unii:13s1s8sf37), titanium dioxide (unii: 15fix9v2jp) (titanium dioxide - unii:15fix9v2jp) - zinc cation 128.8 mg in 1 ml - sunscreen uses: - help prevent sunburn. - if used as directed with other sun protection measures (see directions), decreases the chance of skin cancer and early skin aging caused by the sun. on damaged or broken skin. do not use and ask a doctor if  - rash occurs

United States - English - NLM (National Library of Medicine)

allure labs, inc - zinc oxide (unii: soi2loh54z) (zinc cation - unii:13s1s8sf37), titanium dioxide (unii: 15fix9v2jp) (titanium dioxide - unii:15fix9v2jp) - zinc cation 128.8 mg in 1 ml - sunscreen uses: - help prevent sunburn. - if used as directed with other sun protection measures (see directions), decreases the chance of skin cancer and early skin aging caused by the sun. on damaged or broken skin. do not use and ask a doctor if  - rash occurs

United States - English - NLM (National Library of Medicine)

allure labs, inc - zinc oxide (unii: soi2loh54z) (zinc cation - unii:13s1s8sf37), titanium dioxide (unii: 15fix9v2jp) (titanium dioxide - unii:15fix9v2jp) - zinc cation 128.8 mg in 1 ml - sunscreen uses: - help prevent sunburn. - if used as directed with other sun protection measures (see directions), decreases the chance of skin cancer and early skin aging caused by the sun. on damaged or broken skin. do not use and ask a doctor if  - rash occurs

United States - English - NLM (National Library of Medicine)

american regent, inc. - zinc sulfate (unii: 89ds0h96tb) (zinc cation - unii:13s1s8sf37) - zinc sulfate injection is indicated in adult and pediatric patients as a source of zinc for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. zinc sulfate injection is contraindicated in patients with known hypersensitivity to zinc [see warnings and precautions (5.6)] risk summary administration of the approved recommended dose of zinc sulfate injection in parenteral nutrition is not expected to cause major birth defects, miscarriage, or adverse maternal or fetal outcomes. animal reproduction studies have not been conducted with intravenous zinc sulfate.  the estimated background risk of major birth defects and miscarriage for the indicated populations is unknown.  all pregnancies have a background risk of birth defect, loss, or other adverse outcomes.  in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. clinical considerations disease-associated maternal and/or embryo-fetal risk deficiency of trace elements, including zinc, is associated with adverse pregnancy and fetal outcomes. pregnant women have an increased metabolic demand for trace elements, including zinc.  parenteral nutrition with zinc should be considered if a pregnant woman’s nutritional requirements cannot be fulfilled by oral or enteral intake. risk summary zinc is present in human milk. administration of the approved recommended dose of zinc sulfate injection in parenteral nutrition is not expected to cause harm to a breastfed infant. there is no information on the effects of zinc sulfate on milk production. the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for zinc sulfate injection and any potential adverse effects on the breastfed infant from zinc sulfate injection or from the underlying maternal condition. zinc sulfate injection is approved for use in the pediatric population, including neonates, as a source of zinc for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. safety and dosing recommendations in pediatric patients are based on published literature describing controlled studies of zinc-containing products in pediatric patients [see dosage and administration (2.2)] . because of immature renal function, preterm infants receiving prolonged parenteral nutrition treatment with zinc sulfate injection may be at higher risk of aluminum toxicity [see warnings and precautions (5.3)] . reported clinical experience with intravenous zinc sulfate has not identified a difference in zinc requirements between elderly and younger patients.  in general, dose selection should be individualized based on the patient’s clinical condition, nutritional requirements, and additional nutritional intake provided orally or enterally to the patient.

United States - English - NLM (National Library of Medicine)

piramal critical care inc. - zinc sulfate (unii: 89ds0h96tb) (zinc cation - unii:13s1s8sf37) - zinc sulfate injection is indicated in adult and pediatric patients as a source of zinc for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. zinc sulfate injection is contraindicated in patients with known hypersensitivity to zinc [ see warnings and precautions ( 5.6) ]. risk summary administration of the approved recommended dose of zinc sulfate injection in parenteral nutrition is not expected to cause major birth defects, miscarriage, or adverse maternal or fetal outcomes. animal reproduction studies have not been conducted with intravenous zinc sulfate. the estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. clinical considerations disease-associated maternal and/or embryo-fetal risk deficiency of trace elements, including zinc, is associated with adverse pregnancy and fetal outcomes. pregnant women have an increased metabolic demand for trace elements, including zinc. parenteral nutrition with zinc should be considered if a pregnant woman’s nutritional requirements cannot be fulfilled by oral or enteral intake. risk summary zinc is present in human milk. administration of the approved recommended dose of zinc sulfate injection in parenteral nutrition is not expected to cause harm to a breastfed infant. there is no information on the effects of zinc sulfate on milk production. the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for zinc sulfate injection and any potential adverse effects on the breastfed infant from zinc sulfate injection or from the underlying maternal condition. zinc sulfate injection is approved for use in the pediatric population, including neonates, as a source of zinc for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. safety and dosing recommendations in pediatric patients are based on published literature describing controlled studies of zinc-containing products in pediatric patients [see dosage and administration ( 2.2)] . because of immature renal function, preterm infants receiving prolonged parenteral nutrition treatment with zinc sulfate injection may be at higher risk of aluminum toxicity [see warnings and precautions ( 5.3)] . reported clinical experience with intravenous zinc sulfate has not identified a difference in zinc requirements between elderly and younger patients. in general, dose selection should be individualized based on the patient’s clinical condition, nutritional requirements, and additional nutritional intake provided orally or enterally to the patient.

United States - English - NLM (National Library of Medicine)

anazaohealth corporation - sincalide (unii: m03giq7z6p) (sincalide - unii:m03giq7z6p) - sincalide 3 ug - sincalide may be used: to stimulate gallbladder contraction, as may be assessed by various methods of diagnostic imaging, or to obtain by duodenal aspiration a sample of concentrated bile for analysis of cholesterol, bile salts, phospholipids, and crystals; to stimulate pancreatic secretion (especially in conjunction with secretin) prior to obtaining a duodenal aspirate for analysis of enzyme activity, composition, and cytology;  to accelerate the transit of a barium meal through the small bowel, thereby decreasing the time and extent of radiation associated with fluoroscopy and x-ray examination of the intestinal tract gallbladder stones (stimulation of gallbladder contraction in patients with small gallbladder stones may lead to the evacuation of the stones from the gallbladder resulting in their lodging in the cystic duct or in the common bile duct; however, this is unlikely with usual doses of sincalide since complete contraction of the gallbladder is not induced.)

Philippines - English - FDA (Food And Drug Administration)

northfield labs inc - zinc - syrup - 20mg (equivalent to 55mg zinc sulfate) per 5ml

Philippines - English - FDA (Food And Drug Administration)

northfield labs inc - zinc (as zinc sulfate monohydrate) - syrup equivalent to 10 mg elemental zinc) - 10 mg per ml

Philippines - English - FDA (Food And Drug Administration)

hizon labs inc - zinc sulfate monohydrate - syrup - 55 mg / 5 ml (equi. to 20mg elemental zinc)

Philippines - English - FDA (Food And Drug Administration)

hizon labs inc - zinc sulfate monohydrate - syrup (oral drops) - 27.5mg / ml (equiv. to 10 mg elemental zinc)